Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04704934 |
Recruitment Status :
Recruiting
First Posted : January 12, 2021
Last Update Posted : February 21, 2024
|
Sponsor:
Daiichi Sankyo
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Daiichi Sankyo
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | April 15, 2024 |
Estimated Study Completion Date : | November 15, 2024 |